Drug intelligence / Profile preview

etelcalcetide

Development stage: Approved
Lead developer: Amgen
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

Etelcalcetide is a synthetic peptide and calcimimetic agent used to treat secondary hyperparathyroidism in adults with chronic kidney disease (CKD) who are on hemodialysis. It acts as an allosteric agonist of the extracellular calcium-sensing receptor (CaSR) on parathyroid chief cells, enhancing the receptor's activation by extracellular calcium and thereby reducing parathyroid hormone (PTH) secretion. Etelcalcetide is administered intravenously at the end of dialysis sessions. The drug was approved under the brand name Parsabiv in 2017 for this indication[1][2][3][4][5][6].

Brand names: Parsabiv
Other names: etelcalcetideEtelcalcetide HClTelcalcetide hydrochlorideVelcalcetide hydrochloride

Targets

CaSR (Extracellular calcium-sensing receptor)

Beyond the preview

Go deeper on etelcalcetide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etelcalcetide.

Explore the full profile